NFE2L3 inhibited breast cancer cell proliferation and migration by inhibiting AKT/ID3 axis; Silencing NFE2L3 increased the percentage of cell number in S and G2/M phase, and decreased these in G0/G1 phase. Here, AKT1 is linked to breast carcinoma.